that lack existing treatments, we uncover their underlying mechanisms and develop therapies that restore function and delay disease progression. With our streamlined drug discovery process, we have reduced the timeline from disease identification to human trials from six years to just nine months. Through collaborations with pharmaceutical companies, QRGenetics has already contributed to over 20 successful cases, demonstrating our commitment to advancing healthcare solutions for some of the most challenging medical conditions. Our goal is to transform the pharmaceutical industry, further enhancing our GenAI capabilities to deliver life-changing solutions to millions worldwide.